Irvine, CA (PRWEB) September 28, 2011
Curexo USA today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 8,021,847 titled “Microvesicle-Based Compositions and Methods” with claims that cover the use of all types of RNA isolated from microvesicles obtained from blood samples and other biological fluids for the detection of cancer. The patent is the first issued from the Company's portfolio, which includes three additional pending applications in the U.S. and certain filings in EU, Japan, Canada, Australia, and China.
The priority date of Curexo USA’s portfolio is June 2, 2004, which predates the earliest priority date of pending U.S. applications in the field filed by others by more than three years.
“We believe that our emerging patent portfolio will enable the development of tests for the detection of cancer that will have long-term market exclusivity,” said Soonkap Hahn, PhD, Chairman and CEO of Curexo USA. “This first patent is an important component of our intellectual property portfolio covering all types of RNA isolated from microvesicles obtained from blood and other biological fluids for the detection of cancer, including early stage tumors when they are most treatable.”
Exosomes are a type of microvesicle shed into the bloodstream from normal and malignant cells, including early stage tumors. Exosomes can be isolated from blood collected by regular venipuncture using standard laboratory protocols. Exosomes contain mRNAs and microRNAs that can be isolated and analyzed by standard laboratory protocols. Exosomes from malignant cells have specific mRNA and microRNA profiles that may be used to identify the presence, type, and potentially the stage of virtually any type of solid tumor.
Curexo believes that RNAs present in exosomes isolated from blood obtained by a standard venous draw can be used to develop laboratory tests for a broad range of oncology applications, including: early detection of most types of cancer in an asymptomatic population; detection of metastases; diagnose a primary cancer and identify the cancer subtype; predict prognosis and direct treatment; and monitor treatment efficacy and disease progression or recurrence.
The incidence of most types of cancer increases rapidly after age 50. The large and rapidly growing aging populations in the United States, Japan, Western Europe and other developed countries provide an enormous need for the early detection of cancer.
Early detection and treatment of cancer significantly improves the survival rate of patients with some types of solid tumors. There is widespread use of several minimally-invasive laboratory tests or procedures (e.g. Pap Smear for cervical cancer; mammography for breast cancer; X-ray for lung cancer; PSA for prostate cancer; fecal occult blood and colonoscopy for colorectal cancer) intended to provide early detection of a specific type of cancer in an asymptomatic population when it can be treated with high cure rates. Some of these tests are considered to be more reliable than others. For several important types of cancer, there is no method of early detection that has shown to lead to reduced mortality. In addition, none of the widely used methods detects more than one type of cancer.
A potentially unique feature of tests based on Curexo USA’s patent is the possibility of early detection of virtually all types of cancer in an asymptomatic population from one blood sample. A blood sample could be obtained in association with an annual checkup.
About Curexo USA:
Curexo USA, located in Irvine, CA, was founded in 2006 by Soonkap Hahn, PhD in collaboration with Curexo, Inc. (a KOSDAQ-listed corporation based in Seoul, Korea) as a subsidiary conducting life sciences R & D. The Company now operates as a privately-held technology incubator. Other R & D interests include bioerodible polymers for drug delivery systems.